Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease
复制标题
DOI：
10.1681/asn.v131170
复制
发表时间：
2002-01-01
影响因子：
13.6
通讯作者：
Fliser, D
中科院分区：
文献类型：
--
作者：
Kielstein, JT;Böger, RH;Fliser, D
在尿毒症患者中，内源性一氧化氮合酶抑制剂不对称二甲基精氨酸（ADMA）的血液浓度增加与动脉粥样硬化的严重程度和过度的心血管死亡率有关。对44例确诊为原发性慢性肾脏病且未接受治疗的非吸烟患者在肾脏疾病不同阶段的ADMA水平和几种传统的心血管危险因素进行了评估。通过菊粉清除技术评估真实GFR。为了进行比较，对年龄、性别和体重指数相匹配的非吸烟受试者进行了检查。平均血浆ADMA浓度显著高于对照组（P
In patients with uremia, increased blood concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) have been linked to the severity of atherosclerosis and to excess cardiovascular mortality. The ADMA levels and several traditional cardiovascular risk factors were assessed in 44 untreated nonsmoking patients with confirmed primary chronic renal disease at different stages of renal disease. True GFR was assessed by means of the inulin-clearance technique. For comparison, nonsmoking subjects matched with respect to age, gender, and body-mass index were examined. Mean plasma ADMA concentration was markedly higher (P